Laurus Labs , a leading pharmaceutical and biotechnology company, has announced robust financial results for the second quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company reported a substantial increase in revenue, reaching ₹1,653 crore in Q2, marking a 35% year-on-year growth. This performance was primarily driven by strong execution in the Contract Development and Manufacturing Organization (CDMO) segment and supported by growth in the Generics business.

Laurus Labs' profitability saw a remarkable improvement:

The company's gross margins expanded by 470 basis points to 59.9%, attributed to a favorable product mix.

Segment Performance

The CDMO segment continued its strong momentum, with revenues increasing by 53% year-on-year to ₹518 crore in Q2. The small molecules division within CDMO grew by 58%, while the Bio division saw an 18% increase.

The Generics business also performed well, with revenues growing 28% year-on-year to ₹1,135 crore. Within this segment, Finished Dosage Formulations (FDF) showed impressive growth of 58%, while the API business grew by 11%.

Strategic Developments

Laurus Labs announced significant investments to secure future growth:

1. Land Allocation: The company has been allotted 532 acres of land by the Government of Andhra Pradesh to create a state-of-the-art pharma complex in Vizag.

2. Investment Plan: Laurus Labs plans to invest over $600 million in pharmaceutical manufacturing and R&D over the next several years, potentially creating 6,350 employment opportunities.

3. Strategic Investment: The company has made a $2 million investment in Aarvik Therapeutics to access next-generation Antibody-drug conjugates (ADC) technology and R&D capabilities.

4. Capacity Expansion: Ongoing expansion of CMO oral dosage capacity and construction of new facilities for gene therapy and ADC in Hyderabad, as well as a microbial fermentation facility in Vizag.

Dividend Announcement

The Board of Directors has approved an interim dividend of ₹0.80 per equity share (40%).

Management Commentary

Dr. Satyanarayana Chava, Founder & Chief Executive Officer, commented on the results, stating, "We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects ongoing expansion of CDMO business, supported by sustained growth in Generics."

V V Ravi Kumar, Executive Director & Chief Financial Officer, added, "Our strong Q2 performance was in line with expectations. We are pleased to report that fundamentals of our business remain strong, with sustained growth momentum in CDMO and Generic business."

Laurus Labs' focus on R&D-driven commercial strategy and investments in high-value CDMO/CMO business opportunities positions the company well for continued growth and value creation for shareholders.

Laurus Labs Limited has announced its financial results for the second quarter of the fiscal year 2025-26, along with an interim dividend declaration. The company's Board of Directors convened on October 23, 2025, to approve these significant corporate actions.

Financial Results Approval

The Board of Directors of Laurus Labs has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. These results have been submitted to the stock exchanges along with limited review reports from the company's statutory auditors, Deloitte Haskins & Sells LLP.

Interim Dividend Declaration

In a move that will likely be welcomed by shareholders, the Board has approved an interim dividend of Rs 0.80 per equity share, which represents 40% of the face value of Rs 2.00 per share for the financial year 2025-26.

Key Dates for Shareholders

For shareholders and potential investors, the following dates are crucial:

The record date is set to determine the eligibility of shareholders for the interim dividend. Investors who are registered as shareholders of Laurus Labs on October 31, 2025, will be eligible to receive the dividend payment.

Board Meeting Details

The Board meeting where these decisions were made commenced at 2:00 PM and concluded at 2:55 PM on October 23, 2025. The company has duly informed the stock exchanges about the outcome of this meeting, in compliance with regulatory requirements.

Investor Access to Financial Results

Laurus Labs has ensured transparency by making the financial results accessible to the public. Investors and interested parties can view the detailed financial results on the company's official website ( www.lauruslabs.com ) as well as on the websites of the BSE ( www.bseindia.com ) and NSE ( www.nseindia.com ).

While the specific financial figures from the Q2 results have not been disclosed in the available information, the approval of results and declaration of an interim dividend suggest that the company's financial position remains stable. Shareholders and market analysts will likely be keen to examine the detailed financial statements to assess Laurus Labs' performance in the current economic environment.

Investors are advised to review the full financial reports and consult with financial advisors before making investment decisions based on this corporate action.